MedTrace Logo

Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence

NCT00463775 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-01-31

No results posted yet for this study

Summary

The objective of the present study is to evaluate the efficacy of topiramate (250mg/day) versus placebo in decreasing aggression and reducing alcohol consumption in patients with borderline personality disorder (BPD) and alcohol dependence (AD).

Conditions

  • Alcohol Dependence
  • Borderline Personality Disorder

Interventions

DRUG

Topiramate

SSRI plus topiramate SSRI plus placebo

Sponsors & Collaborators

  • Elizabeth Ralevski

    lead OTHER

Principal Investigators

  • Elizabeth Ralevski, Ph.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-05-31
Completion
2009-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00463775 on ClinicalTrials.gov